Role of Tissue Plasminogen Activators, Streptokinase and Other Thrombolytics in the Treatment of Myocardial Infarction
Hussam Eljatib *
Al Dhannah Hospital, United Arab Emirates.
*Author to whom correspondence should be addressed.
Abstract
In the United States, coronary artery disease is the most frequently occurring cause of mortality. A century ago, the obstruction of CA was recognized as the root cause of myocardial infarction. Through research, streptokinase was discovered as a beneficial treatment for acute myocardial infarction, lowering mortality. More recent agents, such as tissue plasminogen activators like Tenecteplase, reteplase, and alteplase have also been developed. Today, primary percutaneous coronary intervention and thrombolytic therapy have transformed the way acute myocardial infarction is treated, leading to a significant decrease in cardiovascular-related deaths. This paper offers an outline of the different antifibrinolytic agents used to manage acute myocardial infarction.
Keywords: TPA, streptokinase, thrombolytics, myocardial infarction, cardiac emergency